JP2005506385A5 - - Google Patents

Info

Publication number

JP2005506385A5

JP2005506385A5 JP2003538370A JP2003538370A JP2005506385A5 JP 2005506385 A5 JP2005506385 A5 JP 2005506385A5 JP 2003538370 A JP2003538370 A JP 2003538370A JP 2003538370 A JP2003538370 A JP 2003538370A JP 2005506385 A5 JP2005506385 A5 JP 2005506385A5

Authority

JP

Japan

Prior art keywords

dsrna

strand

medicament

sequence

chain

Prior art date

2002-10-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 claims description 22
• 239000002773 nucleotide Substances 0.000 claims description 16
• 125000003729 nucleotide group Chemical group 0.000 claims description 16
• 108700042226 ras Genes Proteins 0.000 claims description 13
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 12
• 230000000295 complement effect Effects 0.000 claims description 9
• 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 8
• 238000009472 formulation Methods 0.000 claims description 6
• 239000007924 injection Substances 0.000 claims description 6
• 238000002347 injection Methods 0.000 claims description 6
• 239000000203 mixture Substances 0.000 claims description 6
• 238000001802 infusion Methods 0.000 claims description 5
• 239000002904 solvent Substances 0.000 claims description 4
• 101710113436 GTPase KRas Proteins 0.000 claims description 3
• 230000037406 food intake Effects 0.000 claims description 3
• 230000014509 gene expression Effects 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• 108020004705 Codon Proteins 0.000 claims 8
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
• 229940009098 aspartate Drugs 0.000 claims 4
• 239000003094 microcapsule Substances 0.000 claims 3
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 239000004475 Arginine Substances 0.000 claims 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
• 235000004279 alanine Nutrition 0.000 claims 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
• 235000009697 arginine Nutrition 0.000 claims 2
• 230000037396 body weight Effects 0.000 claims 2
• 230000006552 constitutive activation Effects 0.000 claims 2
• 235000018417 cysteine Nutrition 0.000 claims 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
• 230000009368 gene silencing by RNA Effects 0.000 claims 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
• 239000002088 nanocapsule Substances 0.000 claims 2
• 201000002528 pancreatic cancer Diseases 0.000 claims 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
• 229920000642 polymer Polymers 0.000 claims 2
• 229920002477 rna polymer Polymers 0.000 claims 2
• 235000004400 serine Nutrition 0.000 claims 2
• 239000000243 solution Substances 0.000 claims 2
• 239000004474 valine Substances 0.000 claims 2
• 235000014393 valine Nutrition 0.000 claims 2
• 241000282472 Canis lupus familiaris Species 0.000 claims 1
• 241000255925 Diptera Species 0.000 claims 1
• 101150040459 RAS gene Proteins 0.000 claims 1
• 108020004566 Transfer RNA Proteins 0.000 claims 1
• 210000000234 capsid Anatomy 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000002504 physiological saline solution Substances 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 230000002601 intratumoral effect Effects 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1